Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulocuplumab plus low-dose cytarabine in newly diagnosed AML
MOH_2017-12-04_000394Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2017
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ulocuplumab and cytarabine in acute myeloid leukemia (AML) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Not reported. Started Sep 2017; status: completed.
02
Drugs
ulocuplumabcytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2017-12-04_000394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-12-04_000394.